Abstract
Although guidelines for individual risk factors for cardiovascular disease (CVD) assist the healthcare provider, management of the global risk profile of patients is the optimal means to minimize risk. Regardless of whether patients have one or more risk factors, elevated lipid values are generally considered to be a major contributor to global CVD risk. Therefore, reduction of lipid levels is one of the most effective methods to reduce risk of CVD. The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor class of drugs (also known as statins) has documented clinical benefits for reducing the incidence of myocardial infarction, stroke, death from CVD, and total death. Despite widespread acknowledgment of the very favorable benefit-to-risk ratio of the statins, most at-risk patients either are not being treated or are not at the goals defined by the National Cholesterol Education Program.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
